Observational studyMedicine2020
A cross-sectional study: Associations between sarcopenia and clinical characteristics of patients with type 2 diabetes.
Observational study in Medicine, 2020. The graph read 4 numbers from its abstract, feeding 1 cell of the map, but none could be read as for or against, so it casts no vote. It also reports 4 associations that do not count as treatment evidence, such as OR 0.16 (0.03 to 0.97) for body weight & composition. Cited by 38 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
Read, but not usablea number the graph found but could not read as for or against
BMI (body mass index) (OR: 0.365, 95%CI: 0.236-0.661), exercise (OR: 0.016, 95%CI: 0.001-0.169), female (OR: 0.000, 95%CI: 0.00-0.012), metformin (OR: 0.159, 95%CI: 0.026-0.967) and TSM (trunk skeletal muscle mass) (OR: 0.395, 95%CI: 0.236-0.661) were protective factors for sarcopenia.Sarcopenia in patients with T2DM is associated with increased age, increased TFM and increased FT4 level.
BMI (body mass index) (OR: 0.365, 95%CI: 0.236-0.661), exercise (OR: 0.016, 95%CI: 0.001-0.169), female (OR: 0.000, 95%CI: 0.00-0.012), metformin (OR: 0.159, 95%CI: 0.026-0.967) and TSM (trunk skeletal muscle mass) (OR: 0.395, 95%CI: 0.236-0.661) were protective factors for sarcopenia.Sarcopenia in patients with T2DM is associated with increased age, increased TFM and increased FT4 level.
BMI (body mass index) (OR: 0.365, 95%CI: 0.236-0.661), exercise (OR: 0.016, 95%CI: 0.001-0.169), female (OR: 0.000, 95%CI: 0.00-0.012), metformin (OR: 0.159, 95%CI: 0.026-0.967) and TSM (trunk skeletal muscle mass) (OR: 0.395, 95%CI: 0.236-0.661) were protective factors for sarcopenia.Sarcopenia in patients with T2DM is associated with increased age, increased TFM and increased FT4 level.
BMI (body mass index) (OR: 0.365, 95%CI: 0.236-0.661), exercise (OR: 0.016, 95%CI: 0.001-0.169), female (OR: 0.000, 95%CI: 0.00-0.012), metformin (OR: 0.159, 95%CI: 0.026-0.967) and TSM (trunk skeletal muscle mass) (OR: 0.395, 95%CI: 0.236-0.661) were protective factors for sarcopenia.Sarcopenia in patients with T2DM is associated with increased age, increased TFM and increased FT4 level.
clause the extractor read what became the number
Where it lands on the map
Rows are treatments, columns are outcomes. The coloured squares are the cells this paper feeds, coloured by the vote it casts there. Click one to jump to what this paper adds to it.
What it adds to each cell
For every cell the paper feeds: the belief in the claim with and without this paper, and this paper's estimate drawn against every other readable study in the cell. The ringed dot is this paper.
Metformin×body weight & composition
No readable resultOpen on the map →What to test next →19 readable studies in this cell: 7 favour the treatment, 6 find no difference, 6 favour the comparator.
This paper's own estimate is on a different scale from the rest of the cell, so it is not drawn here.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 3 syntheses or guidelines pooled it, 95 citations in OpenAlex.
- Factors associated with sarcopenia in elderly patients with type 2 diabetes mellitus.Frontiers in endocrinology · 2026Pooled it
- Chronic obstructive pulmonary disease as a risk factor for sarcopenia: A systematic review and meta-analysis.PloS one · 2024Pooled it
- The Prevalence of Sarcopenia in Chinese Older Adults: Meta-Analysis and Meta-Regression.Nutrients · 2021Pooled it
- The effects of dietary protein on physical performance and body composition in middle age and older people having type II diabetes mellitus: a randomized pilot study.European journal of nutrition · 2025Trial
- Changes in glycemic control and skeletal muscle mass indices after dapagliflozin treatment in individuals with type 1 diabetes mellitus.Journal of diabetes investigation · 2023Trial
- Effects of Higher Dietary Protein Intake on Isokinetic Muscle Performance in Older Adults with Type 2 Diabetes Mellitus.Journal of functional morphology and kinesiology · 2026Article
- Metformin for Longevity and Sarcopenia: A Therapeutic Paradox in Aging.Biomedicines · 2026Article
- Circulating Biomarkers as a Window into the Relationship between Sarcopenia and Diabetes: Implications for Effective Management.Current diabetes reviews · 2026Review
- Muscle mass and function in patients with type 2 diabetes mellitus: a characteristic analysis based on sex, age, and BMI.Frontiers in endocrinology · 2026Article
- Sarcopenia in type 2 diabetes mellitus: an imaging review.Frontiers in medicine · 2026Review
- Sex‑specific effects of aging and glycemic control on the association of possible sarcopenia in older adults with type 2 diabetes: a cross-sectional study.Aging clinical and experimental research · 2025Article
- Estimating the Burden of Sarcopenia in Adults With Type 2 Diabetes Mellitus: Implications for Metabolic Health.Cureus · 2025Article
- Sarcopenia and it's influencing factors among adults with asthma, chronic obstructive pulmonary disease, and tuberculosis in Penang, Malaysia.BMC public health · 2025Article
- Nutrient metabolism and complications of type 2 diabetes mellitus: implications for rehabilitation and precision care.Frontiers in nutrition · 2025Review
- The Relationship between physical activity, nutritional status, and sarcopenia in community- dwelling older adults with type 2 diabetes: a cross-sectional study.BMC geriatrics · 2024Article
- The Effect of Chronic Dietary Protein Manipulation on Amino Acids' Profile and Position Sense in the Elderly Suffering from Type 2 Diabetes Mellitus.Journal of functional morphology and kinesiology · 2024Article
- Analysis of Risk Factors for the Association of Sarcopenia in Patients with Type 2 Diabetes Mellitus.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
- Dynapenia and sarcopenia: association with the diagnosis, duration and complication of type 2 diabetes mellitus in ELSA-Brasil.Cadernos de saude publica · 2024Article
- Development and Validation of a Risk Prediction Model for Sarcopenia in Chinese Older Patients with Type 2 Diabetes Mellitus.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
- Sarcopenia and Diabetes: A Detrimental Liaison of Advancing Age.Nutrients · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The marked sentences are the ones the graph read a number from.
Sarcopenia is a geriatric syndrome and it impairs physical function. Patients with type 2 diabetes mellitus (T2DM) are at a higher risk of sarcopenia. The purpose of this study is to explore characteristics of general information and metabolic factors of sarcopenia in patients with T2DM in the northeast of China, and provide information for the prevention and treatment of sarcopenia in clinical practice.Patients with T2DM aged ≥65 were recruited in Changchun from March 2017 to February 2018. Questionnaires of general information, physical examination, laboratory and imaging examination were conducted. The patients were assigned into sarcopenia group and non-sarcopenia group according to the diagnostic criteria proposed by Asian working group for sarcopenia (AWGS), and the differences between 2 groups were analyzed.A total of 132 participants were included in this study, of which, 38 (28.8%) were diagnosed with sarcopenia. 94 (71.2%) were with no sarcopenia. Logistic regression analysis showed that age (OR: 1.182, 95%CI: 1.038-1.346), trunk fat mass (TFM) (OR: 1.499, 95%CI: 1.146-1.960) and free thyroxine (FT4) (OR: 1.342, 95%CI: 1.102-1.635) were independent risk factors for sarcopenia. BMI (body mass index) (OR: 0.365, 95%CI: 0.236-0.661), exercise (OR: 0.016, 95%CI: 0.001-0.169), female (OR: 0.000, 95%CI: 0.00-0.012), metformin (OR: 0.159, 95%CI: 0.026-0.967) and TSM (trunk skeletal muscle mass) (OR: 0.395, 95%CI: 0.236-0.661) were protective factors for sarcopenia.Sarcopenia in patients with T2DM is associated with increased age, increased TFM and increased FT4 level. Regular exercise, female, metformin administrations, high BMI and increased TSM are associated with lower risk of sarcopenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.